What Real Semaglutide Reviews Say About Fatigue, Hair Loss, and the Lawsuit

What do real semaglutide reviews actually say?

"Semaglutide reviews" on a search results page actually points to three different things wearing one name: Reddit threads, star ratings on Drugs.com and WebMD, and a growing pile of five-star testimonials for compounded drops and B12-stacked kits sold direct to consumer. They don't all describe the same product, and conflating them is the single easiest way to misread the pattern.

Start with the aggregate ratings, since they're the steadiest read. On Drugs.com, semaglutide as a molecule — folding together brand and off-label mentions across both diabetes and weight-loss use — averages 6.9 out of 10 across 3,157 reviews, with 56% positive and 20% negative. Narrow that to weight-loss use specifically and the number improves to 7.3 out of 10 across 1,035 reviews, with 62% positive and 18% negative. That's a wider, messier pool than the brand-specific Ozempic and Wegovy pages some other roundups cite separately — it includes people who never specify which product they're actually taking.

Reddit tells a rougher-edged but consistent story. A peer-reviewed 2026 analysis in Nature Health examined more than 410,000 Reddit posts mentioning semaglutide or tirzepatide, isolating just over 67,000 users who self-reported actually using one of the drugs. Just under half of them, 43.5%, described at least one side effect in their posts. Among the specific complaints tallied, nausea led at 36.9%, fatigue followed at 16.7%, then vomiting at 16.3%, constipation at 15.3%, and diarrhea at 12.6%.

One quick note if it's specifically the branded Wegovy pen experience you're trying to weigh: that's a distinct review pool from the generic, compounded, and drop-form conversation this page is built around, and it deserves its own read — see Wegovy reviews for that specific angle.

The side effects reviewers report most — and how common they really are

Semaglutide's own FDA label for the weight-management dose lists a specific set of adverse reactions occurring in 5% or more of patients: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, and a handful of others including flatulence and reflux. That list is worth reading against the review data above, because it's a near-exact match — the complaints reviewers volunteer aren't a surprise to the manufacturer, they're on the label.

• Fatigue — listed among the label's common (5% or higher) adverse reactions, and frequently tied by reviewers to eating less, moving more, or mild dehydration rather than described as a standalone symptom
• Hair shedding (alopecia) — reported in about 3% of people on semaglutide in the STEP 1 trial versus 0.9% on placebo, rising to 5.3% among those who lost more than a fifth of their body weight, against 2.5% in smaller losers
• Body aches — not on the FDA's common adverse-reaction list, and notably absent from the top five complaints in the large Reddit analysis above, which makes it a real but comparatively smaller theme than its search volume suggests
• GI upset broadly — the largest category on every source checked, and the leading reason people stop treatment: about 6.8% of people on semaglutide discontinued altogether due to side effects, versus 3.2% on placebo, mostly driven by nausea, vomiting, and diarrhea

A separate, not-yet-peer-reviewed analysis posted to medRxiv in 2025, drawing on a health-claims database of nearly 2,000 semaglutide users compared against users of a different weight-loss drug, found semaglutide users were about 50% more likely to report hair loss, with women carrying roughly twice the risk of men. It's a real, specific finding worth naming — and also one flagged by its own authors as a preprint, not yet peer-reviewed, so it belongs in the "worth watching" column rather than the settled-science one.

Do the before-and-after results in reviews match what to expect?

The trial numbers behind semaglutide are public and specific: in STEP 1, the study that established the drug's weight-management dose, participants without diabetes lost close to 15% of their starting body weight on average over 68 weeks. The full breakdown, including how that compares with tirzepatide and what changes for a body already in perimenopause, is covered in GLP-1 before and after rather than repeated here.

Online before-and-after posts skew toward the extremes of that trial average, for a predictable reason: a 2026 mixed-methods study analyzing online semaglutide medication reviews described the pattern as splitting into recognizable camps — people reporting dramatic, life-changing losses, people who quit within the first month over nausea, and a smaller group reporting little to no change despite sticking with treatment. All three groups post, and post loudly; the trial average sits quietly in the middle, describing none of them individually.

One more thing before-and-after threads rarely mention: what happens after the last post. In semaglutide's own trial extension data, people who stopped the medication regained a substantial share of the weight they'd lost within about a year, alongside metabolic markers drifting back in the same direction. A transformation photo is a snapshot, not a permanent state, unless treatment continues.

Compounded and sublingual drops — are these reviews even about the same drug?

This is worth asking before trusting any specific five-star post, because a meaningful share of what gets reviewed under "semaglutide" online was never the finished, FDA-approved product to begin with. Compounded semaglutide remains legal in a narrow, specific sense as of this writing: a state-licensed 503A pharmacy can still prepare it for an individually named patient under a valid prescription, though not simply as an unmodified copy of the commercial drug unless a prescriber documents a clinically meaningful reason for that specific patient. Large-scale 503B bulk compounding is a different story — semaglutide is neither on the FDA's shortage list nor its 503B bulks list, which closes that pathway in practice, and the FDA proposed on April 30, 2026 to exclude semaglutide formally from that bulks list going forward. The public comment period on that proposal closed June 29, 2026, with no final rule issued as of this writing. The fuller pricing and legality picture across providers lives in compounded semaglutide.

Sublingual "drops" are a separate and, frankly, thinner claim. No sublingual GLP-1 product has FDA approval, for semaglutide or any other molecule in this class. Even Rybelsus — the one FDA-approved oral semaglutide tablet — only reaches meaningful blood levels because it's co-formulated with a specific absorption-enhancing ingredient, and its bioavailability still runs a fraction of a percent up to about 1%, which is why it comes with strict empty-stomach, thirty-minute dosing rules. A liquid drop product without that same engineering, and without large-scale outcomes data behind it, has no established mechanism for getting a meaningful dose of the actual peptide into your bloodstream. A glowing review of "sublingual semaglutide drops" may be entirely honest about someone's experience and still be describing a product that delivered little or none of the drug it's named for.

Semaglutide-with-B12 kits sit somewhere in between: the semaglutide portion, if it's genuinely compounded through a licensed 503A pharmacy, is a real medication. The B12 addition, and any claim that it specifically prevents fatigue or boosts energy, hasn't gone through the FDA review that the base drug has — it's a compounding choice, not a studied combination, so a reviewer crediting B12 for their energy levels is reporting an impression, not a trial finding.

The lawsuits showing up alongside reviews — what's actually pending

Yes, there's a real semaglutide lawsuit, and it's specific enough to describe plainly. Thousands of federal cases alleging gastrointestinal injury — gastroparesis, intestinal obstruction, and related complications — from GLP-1 drugs including semaglutide are consolidated into a single multidistrict litigation in the Eastern District of Pennsylvania, overseen by Judge Karen S. Marston. Case counts reported across legal-tracking sites in September 2026 range from roughly 3,800 to just over 4,000, depending on when the count was pulled — a fast-growing docket, not a fixed number. Expert-witness hearings on causation were scheduled for September 2026, well ahead of any bellwether trial, verdict, or settlement, none of which have happened yet. The full docket is public at MDL 3094 in the Eastern District of Pennsylvania.

A second, smaller litigation covers a different claim entirely: vision loss tied to a rare condition called NAION, consolidated into its own multidistrict case since December 2025, with roughly 110 pending actions as of June 2026 — a much smaller docket than the GI litigation, and a separate legal question.

Both are worth understanding as what they are: litigation over whether warnings on an FDA-approved drug were adequate, still being argued, with no court finding yet that semaglutide caused the injuries described. Neither lawsuit names a compounding pharmacy or a drops seller as a defendant, which cuts both ways — it means the litigation doesn't apply directly to a compounded or drop product, but it also means there's no equivalent legal scrutiny happening on that side of the market at all.

What's different about these reviews once you're in perimenopause

Fatigue, hair thinning, joint aches, and digestive changes are also perimenopause's own vocabulary, entirely apart from any drug. That overlap is what makes a Reddit thread genuinely harder to read at 40-plus than it would be at 25: a symptom a poster attributes to semaglutide might be the drug, might be hormones doing what they were already going to do, or might be both layered on top of each other.

The same Nature Health Reddit analysis cited earlier turned up something worth sitting with here specifically: alongside the expected GI complaints, it flagged menstrual irregularities and temperature-related complaints — chills, hot flushes — as under-recognized, self-reported effects not well captured in the drug's official trial data. Those are also two of perimenopause's most defining symptoms, reported by people who may not have mentioned, or been asked, where else in life those changes were already showing up.

A few timing anchors help sort one from the other, without needing a lab test to do it.

• Onset relative to your dose, not your cycle: drug-linked fatigue, aches, and GI upset tend to spike within a day or two of a dose increase and ease over the following one to two weeks — a perimenopausal version of the same symptoms tends to drift and fluctuate on its own schedule, unrelated to your injection day
• Hair-shedding timeline: drug-related shedding (telogen effluvium tied to rapid weight loss) typically starts a few months after your fastest stretch of weight loss and eases once weight stabilizes; see perimenopause hair loss for how the hormonal pattern differs — generally slower to start, more diffuse across the crown and part line, and not tracking a weight curve at all
• Joint pattern: drug-associated aches often read as flu-like and cluster right after an injection; perimenopausal joint aches tend to show up more symmetrically, with morning stiffness, independent of any dosing schedule

None of this requires solving in your head alone — a simple log of symptom onset against dose-change dates, kept for a few weeks, gives a prescriber something concrete to work with, and it's a more useful data point than either "it's definitely the drug" or "it's definitely just perimenopause."

Where reviewers say they got it, and what it actually costs

Across Reddit and forum posts, sourcing tends to sort into three lanes: brand-name Wegovy or Ozempic through insurance and prior authorization, compounded semaglutide through a licensed telehealth prescriber, and drops or B12-stacked kits bought direct from a seller with no clinician review at all. The prices attached to each lane move often enough, and vary widely enough by provider, that repeating specific figures here would go stale fast — the current, sourced numbers live in compounded semaglutide and the cheapest semaglutide options.

The detail that shows up more than price in these threads, and matters more: whether a clinician was actually involved before the product shipped. A listing that skips that step — no intake form, no video visit, no named pharmacy — is the red flag reviewers themselves raise most often, more than any specific dollar amount, because it's the one thing that determines whether anyone confirmed what's actually in the bottle.

So — is semaglutide worth it, based on the reviews?

Pulled together, the honest read is closer to the trial data than either the glowing testimonials or the horror-story threads suggest on their own: most reviewers describe real, meaningful weight loss, a genuine minority describe side effects severe enough to quit, and the complaints that dominate the conversation — fatigue, GI upset, hair shedding, and to a lesser extent body aches — trace mostly to known, labeled effects of the drug and the pace of the weight loss itself, not something reviewers are inventing. The lawsuit is real and worth knowing about, but it's a question about warning labels working through federal court, not evidence the drug is unsafe to take under a prescriber's care.

Where the reviews genuinely diverge by product is the compounded, sublingual, and B12-stacked end of the market, where the honest first question isn't "did this work for the reviewer" but "was this actually semaglutide." That's worth resolving with a specific pharmacy name and a Certificate of Analysis before weighing anyone's star rating at all.